Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down
Bristol-Myers Squibb beat Q4 earnings expectations, but the stock fell due to lowered 2025 revenue guidance and patent ...
Investor's Business Daily on MSN1d
Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook
Bristol Myers walloped sales views Thursday, but Bristol Myers Squibb stock took a hit on a light outlook hamstrung by ...
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 ...
Bristol Myers Squibb Tops Q4 Estimates
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
pharmaphorum1d
BMS extends its cost-cutting drive by another $2bn
BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2024. "We made good progress in 2024, which was capped by a fourth ...
Bristol Myers Earnings Are a ‘Tale of 2 Trends’ as Guidance Falls Short. The Stock Is Falling
Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference ...
Bristol Adds to Cost Cutting With Outlook Missing Estimates
Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...
Bristol-Myers Squibb slips as 2025 outlook disappoints
Bristol-Myers Squibb (SMY) stock falls as its Q4 2024 results beat Street forecasts, but its 2025 outlook fell short of ...
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.